Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay

Neoadjuvant chemotherapy (NAC) has the added advantage of increasing breast conservation rates with equivalent survival outcomes compared with adjuvant chemotherapy. A subset of breast cancer patients who received NAC experienced early failure (EF) during the course of therapy or within a short peri...

Full description

Bibliographic Details
Main Authors: Park, Kyunghee, Choi, Moon Ki, Jung, Hae Hyun, Do, In-Gu, Lee, Kwang Hee, Ahn, TaeJin, Kil, Won Ho, Kim, Seok Won, Lee, Jeong Eon, Nam, Seok Jin, Kim, Duk-Hwan, Ahn, Jin Seok, Im, Young-Hyuck, Park, Yeon Hee
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695201/
id pubmed-4695201
recordtype oai_dc
spelling pubmed-46952012016-01-26 Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay Park, Kyunghee Choi, Moon Ki Jung, Hae Hyun Do, In-Gu Lee, Kwang Hee Ahn, TaeJin Kil, Won Ho Kim, Seok Won Lee, Jeong Eon Nam, Seok Jin Kim, Duk-Hwan Ahn, Jin Seok Im, Young-Hyuck Park, Yeon Hee Clinical Research Paper Neoadjuvant chemotherapy (NAC) has the added advantage of increasing breast conservation rates with equivalent survival outcomes compared with adjuvant chemotherapy. A subset of breast cancer patients who received NAC experienced early failure (EF) during the course of therapy or within a short period after curative breast surgery. In contrast, patients with pathological complete response (pCR) were reported to have markedly favorable outcomes. This study was performed to identify actionable mutation(s) and to explain refractoriness and responsiveness to NAC. Included in this analysis were 76 patients among 397 with locally advanced breast cancer for whom a preoperative fresh-frozen paraffin-embedded tumor block was available for next-generation sequencing using AmpliSeq. The incidence of missense mutations in KRAS was much higher in patients with EF than in other groups (p < 0.01). In contrast, polymorphisms of the cMET gene were found in patients with pCR exclusively (p < 0.01). Impact Journals LLC 2015-05-12 /pmc/articles/PMC4695201/ /pubmed/26009992 Text en Copyright: © 2015 Park et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Park, Kyunghee
Choi, Moon Ki
Jung, Hae Hyun
Do, In-Gu
Lee, Kwang Hee
Ahn, TaeJin
Kil, Won Ho
Kim, Seok Won
Lee, Jeong Eon
Nam, Seok Jin
Kim, Duk-Hwan
Ahn, Jin Seok
Im, Young-Hyuck
Park, Yeon Hee
spellingShingle Park, Kyunghee
Choi, Moon Ki
Jung, Hae Hyun
Do, In-Gu
Lee, Kwang Hee
Ahn, TaeJin
Kil, Won Ho
Kim, Seok Won
Lee, Jeong Eon
Nam, Seok Jin
Kim, Duk-Hwan
Ahn, Jin Seok
Im, Young-Hyuck
Park, Yeon Hee
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
author_facet Park, Kyunghee
Choi, Moon Ki
Jung, Hae Hyun
Do, In-Gu
Lee, Kwang Hee
Ahn, TaeJin
Kil, Won Ho
Kim, Seok Won
Lee, Jeong Eon
Nam, Seok Jin
Kim, Duk-Hwan
Ahn, Jin Seok
Im, Young-Hyuck
Park, Yeon Hee
author_sort Park, Kyunghee
title Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
title_short Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
title_full Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
title_fullStr Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
title_full_unstemmed Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
title_sort molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and ncounter assay
description Neoadjuvant chemotherapy (NAC) has the added advantage of increasing breast conservation rates with equivalent survival outcomes compared with adjuvant chemotherapy. A subset of breast cancer patients who received NAC experienced early failure (EF) during the course of therapy or within a short period after curative breast surgery. In contrast, patients with pathological complete response (pCR) were reported to have markedly favorable outcomes. This study was performed to identify actionable mutation(s) and to explain refractoriness and responsiveness to NAC. Included in this analysis were 76 patients among 397 with locally advanced breast cancer for whom a preoperative fresh-frozen paraffin-embedded tumor block was available for next-generation sequencing using AmpliSeq. The incidence of missense mutations in KRAS was much higher in patients with EF than in other groups (p < 0.01). In contrast, polymorphisms of the cMET gene were found in patients with pCR exclusively (p < 0.01).
publisher Impact Journals LLC
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695201/
_version_ 1613517989401853952

Similar Items